论文部分内容阅读
最近,应用干扰素和阿糖腺甙(Ara-A)对HBsAg阳性的慢性肝病作抗病毒治疗的研究很盛行。选用有关DNA病毒增殖的指标,诸如e抗原、e抗体和DNA多聚酶等进行测定,能较客观地判定HBsAg阳性的慢性肝炎的治疗效果。美国应用Ara-A治疗单纯疱疹脑炎取得非常显著疗效,双盲试验结果,对照组的死亡率高达70%,而给药组的死亡率只有28%。此外,Ara-A已试用于由DNA病毒引起的乙型慢性肝炎的治疗。本文主要报道长
Recently, the use of interferon and glycosides (Ara-A) HBsAg-positive chronic liver disease as antiviral therapy is very popular. Selection of indicators of DNA virus proliferation, such as e antigen, e antibody and DNA polymerase, etc., can be more objective to determine the treatment of HBsAg-positive chronic hepatitis. The United States with Ara-A treatment of herpes simplex encephalitis achieved a very significant effect, double-blind trial results, the control group mortality up to 70%, while the medication group, the mortality rate was only 28%. In addition, Ara-A has been tested for the treatment of chronic hepatitis B due to DNA virus. This article mainly reports long